Clinical Trial Update: Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD) [Phase 2]

View source ↗

Summary

This document summarizes a Phase 2 trial evaluating rituximab as the primary treatment for extensive chronic graft-versus-host disease (GVHD), with the study co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Northside Hospital, Inc. | Conditions: Chronic Graft-versus-host Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-02-24